References of "Deberg, Michelle"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailFibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis.
Henrotin, Yves ULg; Gharbi, Myriam; Mazzucchelli, Gabriel ULg et al

in Arthritis and Rheumatism (2012), 64(7), 2260-7

OBJECTIVE: This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. METHODS: Proteomics analysis ... [more ▼]

OBJECTIVE: This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. METHODS: Proteomics analysis was performed in urine samples from 10 women (mean+/-SD age 76.0+/-5.0 years) undergoing knee replacement surgery due to severe OA and 5 healthy women (mean+/-SD age 25.6+/-2.6 years). Protein content was analyzed by 2-dimensional differential gel electrophoresis. Protein spots that exhibited an OA:control abundance ratio of >/=1.5 were identified by mass spectrometry. Specific enzyme-linked immunosorbent assays were developed and validated in serum obtained from 236 healthy subjects ages 20-64 years and from 76 patients with severe radiologic knee OA (mean+/-SD age 68.8+/-11.9 years). Immunohistochemical analysis was performed on articular cartilage from tibial plateaus. RESULTS: Thirteen proteins within spots that were significantly modified between groups were identified. Two peptides of fibulin 3, named Fib3-1 and Fib3-2, were of particular interest. Two antisera directed against these peptides were used to develop immunoassays. Compared with age-matched healthy subjects, median levels of serum Fib3-1 and Fib3-2 were elevated in OA patients (54.6 pM versus 85.1 pM [P<0.0001] and 144.4 pM versus 191.4 pM [P<0.0001], respectively). Using area under the receiver operating characteristic curve analysis, we demonstrated that Fib3-1 and Fib3-2 levels discriminate between OA and normal populations. Immunostaining revealed the presence of Fib3-1 and Fib3-2 in chondrocytes and in the extracellular matrix of the superficial layer of the fibrillated cartilage. CONCLUSION: Our findings indicate that Fib3-1 and Fib3-2 are potential biochemical markers for the diagnosis of OA. [less ▲]

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailColl2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands.
Punzi, L.; Ramonda, R.; Deberg, Michelle et al

in Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society (2012), 20(6), 557-61

OBJECTIVE: Erosive osteoarthritis of the hand (EHOA) is thought to be an aggressive variant of hand osteoarthritis (HOA) characterised by prominent local inflammation and radiographic aspects of bone ... [more ▼]

OBJECTIVE: Erosive osteoarthritis of the hand (EHOA) is thought to be an aggressive variant of hand osteoarthritis (HOA) characterised by prominent local inflammation and radiographic aspects of bone erosions in interphalangeal (IP) joints. However, rare studies have until now investigated the value of biomarkers in these patients. Thus, we determined Coll2-1, a marker of type II collagen denaturation, its nitrated form (Coll2-1NO2) and myeloperoxidase (MPO) levels in serum of patients with EHOA vs non-EHOA and subsequently evaluated their relationships with disease indices of severity and activity. METHODS: Coll2-1, Coll2-1NO2 and MPO were measured using specific immunoassays in 82 patients, 57 with EHOA, all females, median age 59 (41-74 yrs) and 20 with non-EHOA, all females, median age 55 (43-73 yrs), fulfilling the American College of Rheumatology (ACR) criteria for hand OA. EHOA was characterized by the presence of at least one central bone erosion on radiograph in the IP joints. Patients were also evaluated for disease duration, number of affected (swollen and painful or tender) joints, radiographic score (RS) by Kallman scale and high sensitivity C-reactive protein (hsCRP). RESULTS: Serum levels of MPO were higher in EHOA (230.0 +/- 152.1 ng/ml) than in non-EHOA (160.2 +/- 111.5 ng/ml, P=0.037). Coll2-1NO2 levels trended towards an elevation in EHOA compared non-EHOA (0.40 +/- 0.86 vs 0.22 +/- 0.14 nmol/l, P=0.06), while Coll2-1 levels were not different. Correlations were found for disease duration and both MPO (R(2)=0.48, P=0.001) and Coll2-1NO2 (R(2)=0.73, P=0.01) after the splitting of the population in subgroups according to a cut off value above the 50th percentile. A correlation was found between hsCRP and MPO (R(2)=0.57, P=0.01). CONCLUSIONS: This study clearly demonstrates an elevation of some serum biomarkers in EHOA, in comparison with non-EHOA. In particular, MPO, hsCRP and the ratio Coll2-1NO2/Coll2-1 discriminated the two subsets of hand osteoarthritis (HOA), and a trend was also observed for Coll2-1NO2. These data suggest that these biomarkers could be helpful for the diagnosis of EHOA. [less ▲]

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailUsefulness of specific OA biomarkers, Coll2-1 and Coll2-1NO(2), in the anterior cruciate ligament OA canine model.
Henrotin, Yves ULg; Martel-Pelletier, Johanne; Msika, Philippe et al

in Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society (2012), 20(7), 787-90

Detailed reference viewed: 14 (0 ULg)
Full Text
See detailBIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2011)

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications ... [more ▼]

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 15 (6 ULg)
Full Text
See detailBIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2011)

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications ... [more ▼]

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 17 (6 ULg)
Full Text
See detailBiomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2009)

The invention relates to the identification of a biomarker whose abundance in bodily fluids is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications ... [more ▼]

The invention relates to the identification of a biomarker whose abundance in bodily fluids is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 13 (4 ULg)
Full Text
See detailDETECTION OF SPECIFIC NITRATED MARKERS
Reginster, Jean-Yves ULg; Deberg, Michelle; Henrotin, Yves ULg et al

Patent (2004)

Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to ... [more ▼]

Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein. [less ▲]

Detailed reference viewed: 19 (2 ULg)
Full Text
See detailMETHOD FOR MONITORING COLLAGEN TYPE II DEGRADATION IN CARTILAGE
Reginster, Jean-Yves ULg; Deberg, Michelle; Henrotin, Yves ULg et al

Patent (2004)

A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most ... [more ▼]

A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals ultizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG, located in the helical region of collagen type II. [less ▲]

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailDégradation du cartilage et stress oxydatif chez des patients arthrosiques et souffrant d'arthrite rhumatoide
Deberg, Michelle; Labasse, A; Christgau, S et al

in Revue du Rhumatisme (2003), 70

Detailed reference viewed: 19 (0 ULg)